Related Experiment Video
Updated: Jun 11, 2026
08:04
Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
Published on: June 10, 2025
The genetics of normal platelet reactivity
Thomas J Kunicki1, Diane J Nugent
1Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA.
Blood
|July 9, 2010
Summary
Genome-wide association studies (GWASs) reveal genetic factors influencing platelet function. Most identified genetic signals reside in noncoding DNA, suggesting transcriptional regulation plays a key role.
Area of Science:
- Genetics
- Hematology
- Molecular Biology
Background:
- Platelet function exhibits significant variation due to genetic and environmental factors.
- Previous candidate gene studies identified single nucleotide polymorphisms (SNPs) requiring validation.
- Genome-wide association studies (GWASs) offer a comprehensive approach for genetic analysis.
Purpose of the Study:
- To identify genetic determinants of platelet count and mean platelet volume using GWAS.
- To validate findings from candidate gene studies with more robust methods.
- To explore the role of noncoding genetic variations in platelet function regulation.
Main Methods:
- Genome-wide association studies (GWASs) were conducted on large cohorts of normal subjects.
- Quantitative functional traits, including platelet count and mean platelet volume, were analyzed.
- Genetic loci associated with these traits were identified and mapped.
Main Results:
- The majority of GWAS signals for platelet traits were located in noncoding regions of the genome.
- Fifteen quantitative trait loci (QTLs) associated with mean platelet volume and platelet count were identified.
- One QTL at 12q24 was found to be a risk locus for coronary artery disease.
Conclusions:
- Noncoding genetic variations likely influence platelet function through transcriptional or posttranscriptional mechanisms.
- GWASs provide novel insights into the regulation of hematopoiesis and megakaryopoiesis.
- The identified genetic loci, though small in effect size, contribute to understanding platelet biology and disease risk.
Related Concept Videos
01:18Structure and Function of Platelets
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...